In MM RSK2 signaling has been reported to be associated with FGFR3 (t;4,14) activation [186, 187] and a number of RSK2 inhibitors have been shown to have anti-myeloma activity (Table 6). The gene discussed is FGFR3; the disease is plasma cell myeloma.